Free tool
FAERS Monitor: Edurant
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202022 or its brand name (Edurant, Rilpivirine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,915
Serious
1,297
68% of reports
Hospitalization
399
Death reported
87
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anxiety186
- pain179
- emotional distress156
- anhedonia141
- chronic kidney disease117
- renal failure103
- product dose omission issue100
- viral load increased98
- fatigue96
- depression95
- headache91
- nausea76
- rash67
- foetal exposure during pregnancy63
- osteoporosis63
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 2 |
| 2012 | 16 |
| 2013 | 40 |
| 2014 | 42 |
| 2015 | 109 |
| 2016 | 125 |
| 2017 | 91 |
| 2018 | 131 |
| 2019 | 146 |
| 2020 | 130 |
| 2021 | 179 |
| 2022 | 382 |
| 2023 | 286 |
| 2024 | 145 |
| 2025 | 60 |
| 2026 | 31 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,244 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| viral load increasedSignal | 98 | 284.4 | 233.9 | 26,708 |
| anhedoniaSignal | 141 | 59.2 | 50.5 | 7,982 |
| chronic kidney diseaseSignal | 117 | 16.9 | 14.2 | 1,742 |
| osteoporosisSignal | 63 | 16.8 | 13.2 | 924 |
| emotional distressSignal | 156 | 14.2 | 12.2 | 1,905 |
| renal failureSignal | 103 | 8.5 | 7.1 | 680 |
| foetal exposure during pregnancySignal | 63 | 8.5 | 6.7 | 412 |
| anxietySignal | 186 | 7.2 | 6.3 | 996 |
| depressionSignal | 95 | 4.6 | 3.8 | 266 |
| product dose omission issueSignal | 100 | 3.7 | 3.1 | 200 |
| painSignal | 179 | 3.2 | 2.8 | 277 |
| rash | 67 | 1.7 | 1.3 | 18 |
| headache | 91 | 1.6 | 1.3 | 20 |
| fatigue | 96 | 1.4 | 1.1 | 9 |
| nausea | 76 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.